Why do doctors use treatments that do not work? For many reasons - including their inability to stand idle and do nothing by Doust, Jenny & Del Mar, Chris
doi:10.1136/bmj.328.7438.474 
 2004;328;474-475 BMJ
  
Jenny Doust and Chris Del Mar 
  
 work?
Why do doctors use treatments that do not
 http://bmj.com/cgi/content/full/328/7438/474
Updated information and services can be found at: 
 These include:
Data supplement
 http://bmj.com/cgi/content/full/328/7438/474/DC1
 "Additional references"
 References
 http://bmj.com/cgi/content/full/328/7438/474#otherarticles
11 online articles that cite this article can be accessed at: 
  
 http://bmj.com/cgi/content/full/328/7438/474#BIBL
This article cites 9 articles, 5 of which can be accessed free at: 
Rapid responses
 http://bmj.com/cgi/eletter-submit/328/7438/474
You can respond to this article at: 
  
 http://bmj.com/cgi/content/full/328/7438/474#responses
for free at: 
32 rapid responses have been posted to this article, which you can access
 service
Email alerting
box at the top left of the article 
Receive free email alerts when new articles cite this article - sign up in the
Topic collections
 (485 articles) Other evidence based practice 
  
Articles on similar topics can be found in the following collections 
 Correction
 http://bmj.com/cgi/content/full/328/7447/1066-a
available online at: 
have been appended to the original article in this reprint. The correction is 
A correction has been published for this article. The contents of the correction
 Notes   
To order reprints follow the "Request Permissions" link in the navigation box 
 http://resources.bmj.com/bmj/subscribers
 go to: BMJTo subscribe to 
 on 14 November 2007 bmj.comDownloaded from 
Why do doctors use treatments that do not work?
For many reasons—including their inability to stand idle and do nothing
One of the surprising things about JamesLind’s celebrated trial of citrus fruit for scurvywas not just that he ignored the evidence
from his own trial but that in clinical practice he
continued to advocate treatments that he himself had
found ineffective, including those containing sulphuric
acid.w1 The history of medicine is replete with examples
of treatments once common practice but now known
not to work—or worse, cause harm. Only because the
French surgeon Paré ran out of boiling oil did he
discover that not cauterising gun shot wounds with it
created much less pain and suffering.w2 Leeches and
blood letting were used for thousands of years for
almost everything. Attempts to show that they were
ineffective were resisted with great passion by the
medical profession.w3 More recently, we have had treat-
ment with insulin for schizophrenia and vitamin K for
myocardial infarction.1 2 In case we are all feeling too
smug about silliness in the bad old days, we have the
recent crisis on finding that hormone replacement
therapy does not prevent cardiovascular disease.3 Why
do we still use ineffective treatments?
One reason is that our expectations for the benefits
of treatment are too high. As Voltaire said, “The art of
medicine consists in amusing the patient while nature
cures the disease.” Or, in modern parlance: most drugs
work in only 30% or 50% of people.4 Because patients
so often get better or worse on their own, no matter
what we do, clinical experience is a poor judge of what
does and does not work. Hence the need for
adequately powered randomised controlled trials.
A second reason is we are taught that because medi-
cine is based on the sciences, understanding the patho-
physiology of disease is essential to effective treatment.
And so it is for many treatments. Use of insulin for dia-
betic coma needs a full understanding of the
pathophysiology. Similarly, our appreciation of how
parachutes slow falls means we do not need a placebo
controlled trial of parachutes.5 But we have many exam-
ples where this approach, without empirical testing, is
wrong. Until recently, medical students were taught the
pathophysiological reasons why  blockers are contra-
indicated in heart failure (they are a good treatment for
heart failure); why colloid is more effective than crystal-
loid for fluid replacement (it is worse); and that because
the vascular supply of the scaphoid places it at risk of
non-union, any suspected fracture requires a cast (active
mobilisation results in better outcomes).6 7 Lind’s belief
in the humoral basis of disease caused his resistance to
his own trial evidence, and the medical profession to
reject Louis’s data on blood letting.w4
Even when empiricism is satisfied we can be misled
by looking at the wrong outcome. Fluoride increases
bone density. But it also increases the fracture rate.8
Flecainide for the treatment of supraventricular tachy-
cardia makes the electrocardiogram look normal, but
only after clinical trials (that some thought unethical)
did it emerge that it increases mortality.9
Some treatments have harms that outweigh their
benefits and are not evident in trials. It was only after
licensing in the United States and postmarketing
surveillance that troglitazone was found to cause liver
failure and had to be withdrawn.w5
Let us not stop at ineffective treatments. Much of
the clinical examination and diagnostic testing is more
of a ritual than diagnostically useful. We continue to
order routine blood tests before surgery without
controlled trials to show benefit, and several case series
that show that these tests rarely change outcomes or
even management.10 Alternatively, what was once
perhaps useful is now superseded by better investiga-
tion. When did whispering pectoriloquy last clinch a
diagnosis of pneumonia?
Clinicians want to relieve suffering. We find it diffi-
cult to do nothing (the aphorism “Don’t just do some-
thing, stand there!” seems ludicrous). So we send in the
counselling teams after psychological trauma, prob-
ably making things worse.11 Perhaps it is societal opin-
ion (for which one ear of the medical profession is
always pricked) that errors of omission are more
reprehensible than errors of commission that is at
fault. Is missing a rare diagnosis so much worse than
harm from over-testing?12
What hope is there for not using treatments and
tests that don’t work? Medicine is not just a science—it
is a human activity. It entails ritual, custom, and the
expectations of doctors, patients, and society. To
safeguard against ineffective or harmful health care we
need doctors who want to do the best they can for their
patients, who are willing to continually question their
own managements, and who have readily available
sources of information about what does work.
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Reasons for using ineffective or harmful
treatments
• Clinical experience
• Over-reliance on a surrogate outcome
• Natural history of the illness
• Love of the pathophysiological model (that is wrong)
• Ritual and mystique
• A need to do something
• No one asks the question
• Patients’ expectations (real or assumed)
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Well informed uncertainties about the effects of
treatments
How should clinicians and patients respond?
Uncertainties about the effects of treatmentsare inevitable. Whatever the basis for judg-ments about the likely effects of treatments in
individual patients, there is no escape from the reality
that every such judgment initiates a clinical trial in
which there can be no certainty that an individual
patient will benefit. Sometimes the judgment will draw
on the patient’s past experience of the treatment,
more usually on the clinician’s experience of treating
other patients. Increasingly, clinicians and patients are
taking account of collective experience—the results of
formal evaluations of treatments.1 Maybe this is
because they recognise that treatments can sometimes
do more harm than good, sometimes on a devastating
scale.
What should happen if, after weighing the best
available evidence from collective experience and
taking account of patients’ preferences, residual uncer-
tainty remains about which treatment options should
be chosen? Should the clinician and patient simply
press ahead with yet another poorly controlled clinical
trial? It is surprising that such questions seem to have
been addressed relatively rarely. One attempt to do so
was published in this journal three years ago by a
medical ethicist. “If we are uncertain about the relative
intrinsic merits of [different] treatments,” he wrote,
“then we cannot be certain about those merits in any
given use of one of them—as in treating an individual
patient. So it seems irrational and unethical to insist
one way or another before the completion of a suitable
trial. Thus the answer to the question, “What is the best
treatment for the patient?” is: “The trial.” The trial is the
treatment. Is this experimentation? Yes. But all we
mean by that is choice under uncertainty, plus data col-
lection. Does it matter that the choice is “random”?
Logically, no. After all, what better mechanism is there
for choice under uncertainty?”2
This approach to dealing with uncertainty is
reflected in some of the guidance issued by the
National Institute for Clinical Excellence, and it is
implicit in the NHS Plan, which calls for a doubling in
the numbers of cancer patients participating in clinical
trials.3 The dividends that result from adopting this
response to uncertainty can be substantial: gradual and
important improvements in the prognosis of children
with leukaemia, for example, seem likely to reflect an
expectation among paediatric oncologists that deci-
sions about treatment should be taken within the con-
text of controlled trials, so that uncertainties can be
addressed and reduced.
Strategies for dealing with uncertainty need to be
considered and debated more explicitly. For example,
what does the “quality in health care” movement
have to say? Has it given sufficient attention to the
responsibilities of clinicians and health service
managers to reduce uncertainties about the relative
merits of different treatments, and thus improve the
quality and cost effectiveness of services? What are the
responsibilities of clinicians and managers imple-
menting the clinical governance framework in the
NHS? Should clinicians and institutions be held
accountable for failing to address uncertainties
systematically, as some have suggested they should
be?4 Are strategies for dealing with uncertainty being
addressed in medical schools, and by professional
organisations such as the medical royal colleges,
encouraging clinicians to be more open with patients
about the limitations of treatments and their potential
for harm? And are organisations that endeavour to
represent the interests of the public—the Consumers’
Association, patients’ groups, and the General Medical
Council, for example—taking a sufficiently active role
in promoting discussion about how people should
respond to well informed uncertainties about
treatment choices?
As another medical ethicist has noted, “Doctors
must make many practical decisions, often on the basis
of inadequate information. Too finely developed a
critical faculty, endeavouring disinterestedly to learn
the best that may be known and thought, may
positively inhibit the ability to make such decisions.”5
But there is surely scope for dealing with inadequate
information in ways that can help to identify really
important uncertainties, uncertainties that are often
reflected in dramatic variations in clinical practice and
which cry out for coordinated efforts to improve
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procedure, entailing the implantation of a temporary
device with a neuromodulation unit only slightly larger
than a pager attached to the patient’s regular pant belt.
This stage 1 procedure is performed under local anaes-
thesia and takes less than 45 minutes. If the patient’s
symptoms improve by more than 50%, a permanent
device is implanted in either buttock with a 6 cm
incision. The device can be programmed via an
extracorporeal handheld device for increases or
decreases in power magnitude. The effects on nocturia
have been remarkable, with a reduction of more than
60% in episodes of nocturia, even in patients taking
diuretic medication. Adverse events such as pain at the
implant site, lead migration, infection or skin irritation,
or technical or device related problems are possible in
up to one third of patients, and contraindications such
as benign prostatic hypertrophy, cancer, or urethral
stricture may exclude some patients from candidacy for
the procedure24; in general, however, sacral neuro-
modulation is an effective, safe, and reversible treatment
and offers an important new option22 for patients with
symptoms of urgency, urge incontinence, and nocturia.
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A patient’s success story
Janet Murray, a guard in a correctional facility, is a 42 year old white woman
with an 8 year history of frequency, urgency, and nocturia. Before treatment,
she voided up to 25 times in a 24 hour period; four to six times per night.
Janet could remember experiencing only one normal night’s rest after the
age of 40. She was concerned that her impaired sleep was placing her job at
risk because of drowsiness during the day shift and urinary frequency
(aggravated by a lack of readily available lavatory access) during the night
shift. She had failed bladder training, timed voiding, biofeedback, and
maximum doses of anticholinergic medications, including Ditropan XL,
Detrol LA, and imipramine. Urodynamics showed an unstable bladder.
Luckily, Janet was deemed a candidate for a new method of
neuromodulation with an implantable device called InterStim. Similar to a
cardiac pacemaker but stimulating the third sacral nerve, InterStim has
achieved remarkable results, with a reduction in episodes of nocturia of
more than 60%. One year after implantation, Janet reports having had an
immediate and sustained improvement in her frequency and nocturia. She
now voids a total of six to eight times in 24 hours, with no episodes of
nocturia. Her job is no longer at risk, and her quality of life has improved
substantially.
Corrections and clarifications
Minimally invasive parathyroidectomy
Late insertion of authors’ affiliations in this
editorial led to some confusion over authorship,
which resulted in us adding a third, non-existent,
author, T S Reene (10 April, pp 849-50). The
article had only two authors, F Fausto Palazzo and
Gregory P Sadler, both of whom worked at John
Radcliffe Hospital in Oxford (as specialist registrar
in endocrine surgery and consultant endocrine
surgeon respectively) at the time of writing the
editorial. F Fausto Palazzo is now T S Reeve fellow
in endocrine surgery, Royal North Shore Hospital,
Sydney, Australia. The authorship has been
amended on bmj.com.
Why do doctors use treatments that do not work?
The authors of this editorial, Jenny Doust and
Chris Del Mar, prompted by a rapid response,
have alerted us to an error in their editorial
(28 February, pp 474-5). In the fourth paragraph,
they misquoted reference 9. The authors had
written that flecainide for the treatment of
supraventricular tachycardia makes the
electrocardiogram look normal, whereas the trial
cited investigated use of flecainide for ventricular
tachycardia.
This week in the BMJ: Three days of amoxicillin are
enough for non-severe pneumonia
We inadvertently omitted the word “excess” in this
summary paragraph for the paper by the ISCAP
Study Group (“Three day versus five day treatment
with amoxicillin for non-severe pneumonia in
young children: a multicentre randomised
controlled trial,” 3 April, pp 791-4). The fourth
sentence should read: “Clinical failure was more
likely with non-adherence to treatment at day 5, an
excess respiratory rate of > 10 breaths/minute, and
infection with respiratory syncytial virus.” Although
the reader who alerted us to this error claimed that
the slip prompted him to read the whole article,
introducing errors to attract readers is not a
strategy that we are planning to adopt.
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